Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue
Executive Summary
Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.
You may also be interested in...
First Approval Globally For Gilteritinib, In Japan For AML
First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in launch market Japan looks set to be limited.
Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.
Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market
Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML, analysts say.